Some of these small molecules were validated for coupling with the VEGF-binding site of NRPs, preventing ligand-receptor interactions; for instance, EG00229, developed by Jarvis et al., can inhibit VEGF-R2 phosphorylation, leading to increased cancer cell sensitivity to chemotherapeutic agents paclitaxel and 5-fluorouracil [70] as well as to oncogene targeted drugs [43]. This evidence concerns the gene VEGFA and cancer.